Louvain-la-Neuve, Belgium, June 18th 2018 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of solutions for the diagnosis and treatment of cancer, today announces high level production results achieved by its fixed-energy cyclotron, the Cyclone® KIUBE 300μA, installed at the University Hospital UZ Brussel in Belgium.
IBA’s Cyclone® KIUBE was quickly established as the mid-energy cyclotron of choice after its launch due to its high production capacity and compact size. Cyclone® KIUBE is a true evolutionary cyclotron, meaning that production capacity can be increased step-by-step: from 10, 16, 20 to reach 30 Curies (1110 GBq) of F-18 in a two-hour run, enabling the PET centers to meet the increasing demand for fluorodeoxyglucose (“FDG”), a key element in clinical PET imaging.
Bruno Scutnaire, Head of RadioPharma Solutions at IBA, commented: “Nowadays, radiopharmacies need to produce an increasing amount of FDG in a limited time and to produce numerous other compounds the same day. Short-lived isotopes used in PET cannot be stockpiled and must be produced daily. The Cyclone® KIUBE 300 is the perfect solution with its ability to produce large batches of FDG while offering a large panel of targets and chemistry solutions for non-conventional radioisotope production.”